ArticleFrontiers in oncology2026
Contrast-enhanced ultrasound features of primary renal Ewing-like undifferentiated small round cell neoplasm: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article reports on the diagnosis and treatment of a patient with a renal Ewing-like undifferentiated small round cell neoplasm. The patient, a 56-year-old man, presented to our hospital on March 14, 2025, complaining of "blood clots in the urine for 2 days" and "a mass in the right kidney detected on physical examination 2 days prior." On March 21, 2025, he underwent a "right renal mass needle biopsy" under local infiltration anesthesia. Postoperative pathology: (right renal mass) malignant tumor with necrosis; immunohistochemical findings consistent with renal Ewing-like undifferentiated small round cell neoplasm. Postoperative follow-up: The patient's condition progressed after six cycles of chemotherapy. Immunotherapy combined with anti-angiogenic targeted therapy was planned but proved ineffective; the patient ultimately died of multiple organ failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.